First-in-Human Single Ascending Dose of GLPG0492
Launched by GALAPAGOS NV · May 25, 2010
Trial Information
Current as of June 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • healthy male, age 18-50 years (young subjects) OR ≥60 years (elderly subjects)
- • BMI between 18-30 kg/m², inclusive
- • non-smoker
- Exclusion Criteria:
- • elevated PSA
- • drug or alcohol abuse
About Galapagos Nv
Galapagos NV is a biotechnology company based in Belgium, focused on the discovery and development of innovative medicines to address unmet medical needs. With a robust pipeline of therapies targeting various conditions, including autoimmune diseases and fibrosis, Galapagos leverages its proprietary target discovery platform to identify and validate novel drug candidates. The company emphasizes a commitment to scientific excellence and collaboration, aiming to bring transformative therapies to patients through rigorous clinical trials and a strong emphasis on research and development.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Antwerp, , Belgium
Patients applied
Trial Officials
Florence Namour, PhD
Study Director
Galapagos NV
Sofie Mesens, MD
Principal Investigator
SGS Stuivenberg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials